Nifty
Sensex
:
:
26068.15
85231.92
-124.00 (-0.47%)
-400.76 (-0.47%)

Pharmaceuticals & Drugs

Rating :
59/99

BSE: 543245 | NSE: GLAND

1809.70
21-Nov-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1812
  •  1821.5
  •  1769.9
  •  1817.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  371417
  •  662137154.4
  •  2131
  •  1277.8

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 29,787.14
  • 37.69
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 27,338.75
  • 1.00%
  • 3.12

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 4.71%
  • 2.57%
  • FII
  • DII
  • Others
  • 7.9%
  • 31.48%
  • 1.51%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.81
  • 10.16
  • 15.72

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.13
  • -0.52
  • 4.37

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.26
  • -6.87
  • -3.65

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 38.79

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.20

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 17.51

Earnings Forecasts:

(Updated: 21-11-2025)
Description
2024
2025
2026
2027
Adj EPS
42.4
57.34
72.92
86.59
P/E Ratio
42.68
31.56
24.82
20.90
Revenue
5583.63
6329.18
7195.06
8037.75
EBITDA
1268.92
1545.89
1882.7
2164.06
Net Income
698.53
945.56
1194.63
1427.47
ROA
6.38
8.1
9.38
10.18
P/B Ratio
3.26
3.03
2.75
2.47
ROE
7.82
9.83
11.33
12.28
FCFF
656.09
428.68
734.07
900.19
FCFF Yield
2.37
1.55
2.65
3.25
Net Debt
-2242.48
-2555.12
-3226.05
-4109.77
BVPS
555.41
598.08
657.02
733.86

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
1,486.88
1,405.83
5.77%
1,505.62
1,401.71
7.41%
1,424.91
1,537.45
-7.32%
1,384.05
1,545.15
-10.43%
Expenses
1,172.99
1,108.78
5.79%
1,137.86
1,137.31
0.05%
1,077.39
1,178.80
-8.60%
1,024.10
1,188.76
-13.85%
EBITDA
313.89
297.06
5.67%
367.76
264.40
39.09%
347.52
358.65
-3.10%
359.96
356.39
1.00%
EBIDTM
21.11%
21.13%
24.43%
18.86%
24.39%
23.33%
26.01%
23.07%
Other Income
84.16
59.66
41.07%
57.53
51.43
11.86%
44.03
42.15
4.46%
58.49
37.39
56.43%
Interest
7.82
6.11
27.99%
11.50
5.62
104.63%
7.45
9.96
-25.20%
22.82
5.28
332.20%
Depreciation
106.31
93.83
13.30%
101.05
91.96
9.88%
95.76
92.61
3.40%
96.33
105.34
-8.55%
PBT
283.92
256.78
10.57%
312.74
218.24
43.30%
288.33
298.23
-3.32%
299.30
283.16
5.70%
Tax
100.23
93.25
7.49%
97.26
74.48
30.59%
101.79
105.81
-3.80%
94.61
91.30
3.63%
PAT
183.68
163.53
12.32%
215.48
143.76
49.89%
186.54
192.42
-3.06%
204.69
191.86
6.69%
PATM
12.35%
11.63%
14.31%
10.26%
13.09%
12.52%
14.79%
12.42%
EPS
11.15
9.93
12.29%
13.08
8.73
49.83%
11.32
11.68
-3.08%
12.42
11.65
6.61%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Net Sales
5,801.46
5,616.50
5,664.72
3,624.60
4,400.71
3,462.88
2,633.24
Net Sales Growth
-1.51%
-0.85%
56.29%
-17.64%
27.08%
31.51%
 
Cost Of Goods Sold
2,025.61
2,090.38
2,173.09
1,685.42
2,109.11
1,219.00
836.07
Gross Profit
3,775.85
3,526.12
3,491.63
1,939.17
2,291.60
2,243.88
1,797.18
GP Margin
65.08%
62.78%
61.64%
53.50%
52.07%
64.80%
68.25%
Total Expenditure
4,412.34
4,347.58
4,331.65
2,599.84
2,890.56
2,160.65
1,677.77
Power & Fuel Cost
-
199.15
229.99
124.84
95.05
74.58
78.50
% Of Sales
-
3.55%
4.06%
3.44%
2.16%
2.15%
2.98%
Employee Cost
-
1,401.56
1,256.89
403.26
338.57
311.36
277.66
% Of Sales
-
24.95%
22.19%
11.13%
7.69%
8.99%
10.54%
Manufacturing Exp.
-
347.18
327.19
194.23
179.85
436.84
391.88
% Of Sales
-
6.18%
5.78%
5.36%
4.09%
12.61%
14.88%
General & Admin Exp.
-
206.62
217.36
120.53
94.28
58.66
57.77
% Of Sales
-
3.68%
3.84%
3.33%
2.14%
1.69%
2.19%
Selling & Distn. Exp.
-
27.48
37.46
27.03
40.98
36.69
17.08
% Of Sales
-
0.49%
0.66%
0.75%
0.93%
1.06%
0.65%
Miscellaneous Exp.
-
75.20
89.66
44.53
32.72
23.51
18.82
% Of Sales
-
1.34%
1.58%
1.23%
0.74%
0.68%
0.71%
EBITDA
1,389.13
1,268.92
1,333.07
1,024.76
1,510.15
1,302.23
955.47
EBITDA Margin
23.94%
22.59%
23.53%
28.27%
34.32%
37.61%
36.28%
Other Income
244.21
213.61
170.24
240.46
223.94
134.78
139.17
Interest
49.59
42.00
26.20
7.45
5.24
3.41
7.18
Depreciation
399.45
377.87
344.57
146.74
110.30
98.78
94.59
PBT
1,184.29
1,062.66
1,132.54
1,111.04
1,618.55
1,334.81
992.87
Tax
393.89
364.13
360.08
273.54
406.89
337.85
220.01
Tax Rate
33.26%
34.27%
31.79%
25.94%
25.14%
25.31%
22.16%
PAT
790.39
698.53
772.46
781.04
1,211.66
996.96
772.86
PAT before Minority Interest
790.39
698.53
772.46
781.04
1,211.66
996.96
772.86
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
13.62%
12.44%
13.64%
21.55%
27.53%
28.79%
29.35%
PAT Growth
14.29%
-9.57%
-1.10%
-35.54%
21.54%
29.00%
 
EPS
47.96
42.39
46.87
47.39
73.52
60.50
46.90

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Shareholder's Funds
9,150.74
8,723.84
7,958.72
7,157.62
5,903.24
3,646.24
Share Capital
16.48
16.47
16.47
16.43
16.36
15.49
Total Reserves
9,134.21
8,705.99
7,940.59
7,127.95
5,861.46
3,614.26
Non-Current Liabilities
457.27
488.60
89.68
93.97
80.31
80.78
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
77.66
106.54
3.26
3.82
3.93
4.07
Long Term Provisions
145.99
137.21
0.00
0.00
0.00
0.00
Current Liabilities
1,564.85
1,398.36
729.13
582.02
512.53
359.02
Trade Payables
820.41
767.75
587.35
462.85
396.35
249.09
Other Current Liabilities
619.87
520.07
109.48
76.42
62.36
81.73
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
124.56
110.54
32.30
42.75
53.82
28.20
Total Liabilities
11,172.86
10,610.80
8,777.53
7,833.61
6,496.08
4,086.04
Net Block
4,147.23
3,946.75
1,570.55
1,502.19
954.23
968.10
Gross Block
5,613.37
5,011.68
2,294.95
2,081.32
1,430.70
1,347.81
Accumulated Depreciation
1,466.14
1,064.93
724.41
579.13
476.46
379.71
Non Current Assets
4,389.91
4,965.66
1,876.73
1,981.54
1,372.44
1,239.75
Capital Work in Progress
150.56
237.88
177.22
190.75
337.81
188.47
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
87.69
119.43
128.96
286.40
77.97
81.52
Other Non Current Assets
4.43
661.59
0.00
2.21
2.43
1.66
Current Assets
6,782.94
5,645.15
6,900.81
5,852.08
5,123.64
2,846.29
Current Investments
0.00
0.00
0.00
154.87
0.00
0.00
Inventories
1,685.22
1,655.24
1,945.30
1,185.67
1,275.17
756.28
Sundry Debtors
1,516.53
1,558.69
871.39
1,074.81
670.97
601.78
Cash & Bank
2,556.21
1,839.43
3,770.68
3,093.44
3,005.75
1,325.19
Other Current Assets
1,024.98
102.61
91.00
96.75
171.75
163.03
Short Term Loans & Adv.
875.13
489.19
222.44
246.55
87.60
91.80
Net Current Assets
5,218.09
4,246.79
6,171.68
5,270.05
4,611.11
2,487.27
Total Assets
11,172.85
10,610.81
8,777.54
7,833.62
6,496.08
4,086.04

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Cash From Operating Activity
914.73
996.80
363.97
790.77
604.93
700.93
PBT
1,062.66
1,132.54
1,054.58
1,618.55
1,334.81
992.87
Adjustment
211.94
223.60
38.19
-28.27
17.30
32.15
Changes in Working Capital
-6.06
-53.20
-417.94
-393.01
-435.76
-79.94
Cash after chg. in Working capital
1,268.53
1,302.95
674.83
1,197.28
916.35
945.07
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-353.80
-306.15
-310.87
-406.51
-311.43
-244.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,704.74
-1,756.91
1,208.19
-1,002.62
-1,524.00
-766.08
Net Fixed Assets
-140.33
-227.74
-200.10
-503.56
-232.23
Net Investments
-403.83
-2,377.58
154.87
-162.48
-0.55
Others
2,248.90
848.41
1,253.42
-336.58
-1,291.22
Cash from Financing Activity
-433.48
-799.42
14.92
34.90
1,238.46
-6.87
Net Cash Inflow / Outflow
2,185.99
-1,559.53
1,587.08
-176.95
319.39
-72.01
Opening Cash & Equivalents
357.09
1,908.89
318.82
492.46
169.50
236.40
Closing Cash & Equivalent
2,556.21
357.09
1,908.89
318.82
492.46
169.50

Financial Ratios

Standalone /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Book Value (Rs.)
555.40
529.56
483.12
434.84
359.30
234.25
ROA
6.41%
7.97%
9.40%
16.91%
18.84%
18.91%
ROE
7.82%
9.26%
10.34%
18.61%
20.97%
21.29%
ROCE
11.97%
13.63%
14.04%
24.85%
28.00%
27.39%
Fixed Asset Turnover
1.06
1.55
1.66
2.51
2.49
1.95
Receivable days
99.92
78.29
97.99
72.40
67.08
83.41
Inventory Days
108.54
116.00
157.65
102.05
107.06
104.83
Payable days
138.65
113.80
113.72
74.35
96.63
52.71
Cash Conversion Cycle
69.81
80.48
141.92
100.10
77.51
135.53
Total Debt/Equity
0.03
0.04
0.00
0.00
0.00
0.00
Interest Cover
26.30
44.23
142.61
309.77
392.33
139.24

News Update:


  • Gland Pharma reports 12% rise in Q2 consolidated net profit
    4th Nov 2025, 15:28 PM

    The consolidated total income of the company increased by 7.20% at Rs 1,571.04 crore for Q2FY26

    Read More
  • Gland Pharma - Quarterly Results
    4th Nov 2025, 00:00 AM

    Read More
  • Gland Pharma receives USFDA’s approval for Vasopressin in 5% Dextrose RTU Injection
    26th Aug 2025, 12:50 PM

    According to IQVIA, the product had US sales of approximately $45 million for the twelve months ending June 2025

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.